Mar 04th 2013 - Edison Investment Research today published a report on Oxford BioMedica (OXB.L, LSE:OXB, LON:OXB) entitled "Look No Further...". In summary, the report says:
Oxford BioMedica’s investment case is geared to the striking of worthwhile commercial partnerships for its late-stage clinical assets. The next key inflection point is whether Sanofi decides to opt-in for the further development of RetinoStat, a gene-based treatment for “wet” AMD (age-related macular degeneration). A positive outcome would help validate the LentiVector platform and could kick-start additional collaborations. We currently value the company at £58.5m (down from £62.5m).
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »